SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment for the S&P 500 is heavily focused on the upcoming Federal Reserve interest rate decision, with traders debating whether persistent inflation and geopolitical tensions in the Middle East will force a hawkish stance. The community is actively discussing the potential for a "nothing burger" outcome versus a volatile market reaction as participants weigh the impact of higher oil prices and stagnant rate projections on the broader bull trend.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant upward momentum driven by aggressive institutional buying and speculative interest in the edge computing and AI sector. The community remains deeply divided, with bulls pointing to the stock's resilience and growth potential, while skeptics warn of market manipulation, heavy insider selling, and a lack of fundamental profitability.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing significant momentum as it heads into its quarterly earnings report, with investors focused on the company's critical role in the AI memory supply chain and its capacity to meet demand for HBM chips. While some community members anticipate a massive breakout or a stock split, others are closely watching for potential profit-taking and volatility given the stock's substantial run-up and high implied move expectations.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is experiencing heightened market activity driven by anticipation of upcoming US patent approvals for its Precision Timed Release technology and a pending PDUFA date in late May for its ADHD therapeutic, CTx-1301. Community sentiment remains largely bullish, with investors focusing on the company's low float, institutional accumulation, and the potential for a significant revaluation as the company moves toward commercialization.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing intense trading activity as retail and institutional investors debate whether the stock's massive year-to-date rally is justified by surging AI-driven memory demand or is an unsustainable bubble prone to a sharp reversal. The community is heavily focused on upcoming sector catalysts and Micron's earnings report, with bullish traders betting on continued supply shortages while bearish speculators remain active in calling for a significant pullback.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility and heavy retail interest following an explosive IPO, with the community actively debating whether the company's defense-focused drone software and battlefield-proven narrative justify its massive valuation relative to its current financials. Traders are closely watching for potential breakouts past psychological resistance levels, with many speculating on the potential for institutional contracts and multi-day momentum similar to past high-hype market runners.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing high volatility as the market reacts to shifting geopolitical tensions and the upcoming quarterly earnings report. The community is heavily focused on the company's progress with its USV maritime technology and the expectation of future government defense contracts.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm Holdings is currently facing significant volatility as investors weigh strong earnings growth and expansion efforts against macroeconomic concerns, including credit delinquency rates and broader sector weakness. The community remains deeply divided, with many traders actively debating whether the stock's recent pullbacks represent an attractive entry point for a long-term recovery or a warning sign of further downside pressure.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are currently under intense pressure as investors react to a downward revision in full-year guidance and persistent uncertainty surrounding the ongoing CEO search. While some market participants see value in the stock at current multiples, the community remains divided between those bracing for a deeper retracement and those betting on a potential turnaround following long-standing activist involvement.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors aggressively position the stock as a primary infrastructure beneficiary of the burgeoning 'agentic' AI ecosystem. The community is buzzing over the viral adoption of local AI tools like 'Moltbot,' which are driving increased usage of Cloudflare's edge network and tunneling services, sparking momentum despite broader software sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $SLS  $GILD bought $FTSV Magrolimab for $4.9B, based on Phase 1B Trial Data for AML-MR patients Published at ASH.   
  
- SLS009 Phase 2B data in the Same AML-Mr patient Setting, also published at ASH in Dec 2025, is Better - much better, 
and without the toxicity.   
   
Just the SLS009 &quot;secondary asset&quot; has a direct market comp, of $4.9B . . DD 
SLS009 right now is worth 5x 6x the entire SLS mcap.

David Maibaum

bikechain

BringDownThoseReps

6,700% ROI this quarter

Kat Tastrophe

Steve D

Yam Wai Kent

Stephen

nick

$SLS  
Sellas was brilliant in getting itself set up with IMPACT-AML network in Europe. imho that itself added 20% value to the entire business valuation because GPS roll out will be much faster with the championship of this network that includes a patient advocacy group. 
 
https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Enters-Agreement-with-IMPACT-AML-to-Expand-SLS009-Clinical-Program-into-Europe/default.aspx 
 
https://impactaml.eu/

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European enrollment anticipated in Q2 2026 NEW YORK, Jan.

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

IMPACT on Relapsed/Refractory Acute Myeloid Leukemia: the urgency of a new therapeutic paradigm.

IMPACT-AML part of the Cancer Mission cluster

StockTwits Web

SELLAS Life Sciences Group Inc

OnTheBalance

$SLS SLS009 First Patient Dosed in the Pivotal Randomized P2B for Newly Diagnosed Front Line AML-MR patients . . . AML-MR High Risk 
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025019378/566388/CPX-351-Selectively-Benefits-Patients-with-AML-and  
 
CPX-351 is the Standard of Care for AML-MR 
-- Recent Results in the Same Exact Patient Setting as the SLS009 Trial.  
-- MOS of 9.7 Months, Newly Diagnosed, Front line, AML-MR  
 
RECALL - SLS009 MOS of 8.9 Months and Not Reached was for Patients who Failed 1L/Front Line and were Refractory Aza+VEN. 
Dr. Khan / Levy both Said 009 would double or quadruple the Response in Front line.  
BOTTOM BOTTOM LINE: Everyone in the Industry Knows 009 is worth 5x 6x the Current Entire SLS Market Cap.

Gilead Sciences, Inc.

Forty Seven, Inc.

 Magrolimab for $4.9B, based on Phase 1B Trial Data for AML-MR patients Published at ASH.   
  
- SLS009 Phase 2B data in the Same AML-Mr patient Setting, also published at ASH in Dec 2025, is Better - much better, 
and without the toxicity.   
   
Just the SLS009 "secondary asset" has a direct market comp, of $4.9B . . DD 
SLS009 right now is worth 5x 6x the entire SLS mcap.